Willem Pieter

Gastroenterology & Hepatology // MD & PhD // Research & Liver disease // CrossFit & Cycling

[HEPATOLOGY Journal @HEP_Journal]

Original Article

Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction

Van Kleef et al.
#LiverX
https://t.co/Vr0D3A6XcP

[Willem Pieter @wpbrouwer]

Check out our new MAF-5 liver fibrosis risk score for the general population with metabolic dysfunction!
This score outperforms existing scores such as FIB-4 and could be a game changer for clinical care pathways

https://t.co/oShmYVS5Ga

#Livertwitter @AmerGastroAssn @AGA_Gastro

[EASL Education @EASLedu]

#EASLStudio:
📢Anti-NASH drug expected in 2024
10%/25-30% of weight loss needed for effects on inflammation & fibrosis
Semaglutide ➡️ useful as early treatment?
Medications help to lose & maintain weight loss
👍Lifestyle change, combination therapy & multidisciplinary management

[FattyLiverAlliance @FattyLiverA]

Fib-4 is the most widely accepted and used NIT (non-invasive test) for MASLD and MASH initial assessments. In this video fireside chat, @wpbrouwer shares the recent study presented at #easlcongress 2023: "METABOLIC DYSFUNCTION ASSOCIATED FIBROSIS-5 (MAF-5) SCORE ACCURATELY IDENTIFIES AT-RISK LIVER FIBROSIS AND PREDICTS PROGNOSIS IN A POPULATION-BASED SETTING".

From the @EASLnews presentation:

"The MAF-5 is a validated, age-independent, inexpensive referral tool to identify patients at high risk of liver fibrosis in the primary care setting.

• It outperformed other NITs in the primary care setting especially in the younger and older populations and had a stable performance across (heterogeneous) populations

• It was significantly associated with biopsy-proven fibrosis severity in NAFLD/NASH patients

• MAF-5 was significantly associated with all-cause mortality

• The MAF-5 score may therefore be a good alternative for the FIB-4 for use in the referral pathway for liver-health evaluation."

Authors also include, Laurens van Kleef, @FrancqueSven, Jhon E. Prieto-Ortiz, Milan J. Sonneveld, Carlos B. Sanchez-Luque, Robin G. Prieto-Ortiz, Wilhelmus J. Kwanten, Luisa Vonghia, An Verrijken, Christophe De Block, Zouhir Gadi, Harry Janssen, Robert J. de Knegt.

[Joost PH Drenth @joostphdrenth]

💠This is a formidable step forward for @uegjournal
➡️Bears the signature of @KM_Pawlak
🔝work of the @my_ueg trainee editors @juliakasperUEG
@dragos_ci @a_zanetto @AlexandreNuzzo @ArchibugiLivia @MelchiorChloe @Iagorlago @diogolibanio @wpbrouwer @MarcusHollenba1

[Willem Pieter @wpbrouwer]

Very good conference on #NAFLD and #NASH @ the #EASL #NAFLDsummit ! Rotterdam hospitals @ErasmusMC and #sintfranciscusgasthuis represented 💪🏻@EASLedu @EASLnews 📷 by @etrepo

[Willem Pieter @wpbrouwer]

Joining the #MAFLD debate: it’s not alcohol use that drives mortality risk in metabolic associated #fattyliver disease! https://t.co/j8ythjUiQa #livertwitter #alcohol #NAFLD #Hepatology @HEP_Journal

[Marcus Hollenbach @MarcusHollenba1]

Great @UEGJournal editor meeting with my friends @my_ueg House in Vienna @ArchibugiLivia @KM_Pawlak @lelecapurso @wpbrouwer @diogolibanio @dragos_ci @joostphdrenth @MelchiorChloe

[Joost PH Drenth @joostphdrenth]

@UEGJournal new Journal Impact factor 4.623

@dragos_ci
@a_zanetto
@AlexandreNuzzo
@ArchibugiLivia
@MelchiorChloe
@Iagorlago
@diogolibanio
@wpbrouwer
@MarcusHollenba1
@KM_Pawlak

[Joost PH Drenth @joostphdrenth]

Post #ILC2021 session in 🇳🇱 with Ulrich Beuers ✅ Together with @UEGJournal @wpbrouwer on viral hepatitis incl #COVID19 ✅ Great joint effort on stage @my_ueg @EASLnews @phil_newsome7 @tom_marjot @ThomasBerg24 @franconegro57

[Willem Pieter @wpbrouwer]

Onze lieve Teun is geboren ! 12-06-21 💙💙 zoo trots! https://t.co/gTEGMqbzkd

[Joost PH Drenth @joostphdrenth]

Taking @UEGJournal to a new Twitter 🌐

Congrats to

@dragos_ci
@a_zanetto
@AlexandreNuzzo
@ArchibugiLivia
@MelchiorChloe
@Iagorlago
@diogolibanio
@wpbrouwer
@MarcusHollenba1
@KM_Pawlak

@my_ueg
https://t.co/AfXGtqmu9A

[Joost PH Drenth @joostphdrenth]

Happy to share the news that our nationwide 🇳🇱paper on 'Aggressive fluid hydration to prevent post-ERCP pancreatitis (FLUYT): a multicentre, open-label, randomised controlled superiority trial' has been accepted by @LancetGastroHep

❇️trial with 826 patients!

@my_ueg

[Moreno Christophe @MorenoChristop8]

“Dual aetiology fatty liver disease”: A recently proposed term associa... https://t.co/XtkXT6jTOK

[GI Pearls @GI_Pearls]

Episode 47 -January 2021 is out! Covering Malignant polyp recommendations, EOE in pregnancy, HE treatment, etc. #GITwitter #LiverTwitter #MedEd

iTunes - https://t.co/nZwhLZcqE2
Spotify - https://t.co/0ueNC561hb
Stitcher - https://t.co/pMgVaWetQK
Web -https://t.co/lpjWQoO1wC

[Willem Pieter @wpbrouwer]

Check out our new publication which shows an improved long-term #survival for #septic #shock patients treated with #cytosorb @CytoSorbents https://t.co/hyiyi21Dh0

[Joost PH Drenth @joostphdrenth]

Maybe I did not advertise it well enough but....As of yesterday @KM_Pawlak is the Social Media Editor of @UEGJournal I have great confidence that she will exceed all expectations @wpbrouwer @drkeithsiau @AlexandreNuzzo @Iagorlago @diogolibanio @MelchiorChloe @Iagorlago

[Joost PH Drenth @joostphdrenth]

I have great trust in @wpbrouwer & Marcus Hollenbach acting as Search Engine Optimization Editors for @UEGJournal They will do the job and your article in will find its way among the best of the best @dragos_ci @AlexandreNuzzo @MelchiorChloe @Iagorlag
@diogolibanio @my_ueg

[Joost PH Drenth @joostphdrenth]

Inaugural meeting with the @my_ueg trainee editors @WileyEducation Very happy to have these excellent professionals attached to the @UEGJournal @wpbrouwer @KM_Pawlak @AlexandreNuzzo @Iagorlago @diogolibanio

[Willem Pieter @wpbrouwer]

CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock - Sep 25, 2019 https://t.co/AsSL7kIcPk